Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726336 | 1.00 | SLC2A1 (0.55) | SLC2A1KCNH2ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL5726331 | 1.00 | SLC2A1 (0.55) | SLC2A1KCNH2ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL5739137 | 0.89 | SLC2A1 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL5739124 | 0.89 | SLC2A1 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL5739145 | 0.89 | SLC2A1 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL5726549 | 0.88 | SLC2A1 (0.59) | SLC2A1KCNH2ALDH1A1 | |
| SCHEMBL5726926 | 0.88 | SLC2A1 (0.58) | SLC2A1KCNH2ALDH1A1LMNA | |
| SCHEMBL5726167 | 0.88 | SLC2A1 (0.57) | SLC2A1KCNH2 | |
| SCHEMBL5726932 | 0.88 | SLC2A1 (0.58) | SLC2A1KCNH2ALDH1A1LMNA | |
| SCHEMBL5726937 | 0.88 | SLC2A1 (0.58) | SLC2A1KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719770-A2 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | SLC2A1 3990/4885KCNH2 1839/4885ALDH1A1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.